• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The use of orally administered L-arginine in conjunction with a topical preparation for producing enhanced blood flow in tissue thus causing beneficial effects such as warming cold tissue of the hands and feet, promoting hair growth on bald scalp tissue, promoting healing of superficial ulcers such as leg ulcers in persons with diabetes, and overcoming male erectile failure (impotence) is disclosed. Specifically, use of orally administered L-arginine in conjunction with this is topical preparation provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the cold tissue. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of sodium chloride. This preparation, when topically applied to cold tissue, warming begins within 10 to 45 minutes and is sustained for periods as long as 2 to 18 hours. Further this preparation when applied nightly to bald scalp tissue for a period of time causes substantial growth of hair on the bald scalp, causes the healing of superficial ulcers such as leg ulcers and overcomes impotence.
    公开号:US20010002405A1
    申请号:US09/734,096
    申请日:2000-12-11
    公开日:2001-05-31
    发明作者:Eric Fossel
    申请人:Fossel Eric T.；
    IPC主号:A61Q19-00
    专利说明:
    [0001] 1. Field of the Invention [0001]
    [0002] This invention relates to the use of L-arginine orally alone or in conjunction with topical application of a cream, gel, or other vehicle which contains substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as warming of cold or cool tissues, growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed, relief of impotence, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply. [0002]
    [0003] 2. Prior Art [0003]
    [0004] Approaches to improving local blood flow have been many and consist of both systemic and topical approaches. Many beneficial effects could be obtained should improvement in local blood flow be achieved since impairment of local blood flow causes a variety of negative consequences. Among these are cold hands and feet, baldness, leg ulcers, certain forms of impotence, as well as a variety of other things. Approaches to warming cold tissue including cold hands, fingers, feet and toes constitute one section of the prior art. Many persons suffer from cold hands, feet or other body parts. This is often caused by insufficient blood flow in the cold tissue. Previously cold hands or feet have been treated by wearing warm socks or gloves, sometimes even socks or gloves which are mechanically heated. The use of hot packs and glove or shoe inserts which generate heat through chemical reactions has also been a potential solution. Certain liniments which are essentially irritants, such as those containing the red pepper derived substance, capsicum fall into this category. More recently, topical creams containing nitroglycerine have been used. See H. Natsuda et al., [0004] Ryumachi 34, 849 (1994). All of these approaches work at one level or another though are often extremely transient in nature. Nitroglycerine creams also have the disadvantage that nitroglycerine is a cardioactive drug, raising concerns of effects on the heart.
    [0005] It has been recognized that deficiencies in blood flow in the scalp occur in male pattern baldness. See G. Duplechain et al., [0005] J. Lousiana State Med Soc. 146, 7 (1994); P Klemp et al., J Invests Dermatol 95, 725 (1989); S Toshitani et al., J Dermatol 17, 240 (1990). Topical minoxidil has been used as an agent for hair growth in male pattern baldness with varying results. Though the suggestion has been made that minoxidil operates through increase in the blood supply to the scalp, many investigators have failed to show such an effect. See E de Boer et al., Acta Dermato- Venereoligica 68, 271 (1988); C Bunker et al., British J Derm 117, 668 (1987).
    [0006] The fundamental fact that cold tissue of the hands, fingers, feet and toes as well as other cold tissue is caused by insufficient blood flow to the tissue has been suggested. It has further been suggested by some that the use of increased blood flow through relaxation of blood vessels, particularly small and very small vessels may be of use in warming cold tissue. However reasonable this suggestion, many attempts to demonstrate warming by use of agents which produce vasodilation and therefore increased blood flow have produced negative results. See N Dietz et al., [0006] J Appl Physiol 76, 2047 (1994); S Whitmore et al., J Rheumatol 22, 50 (1995); S Singh et al., Eur J Clin Invest 25, 182 (1995). The only report of modest temporary success involved the use of nitroglycerine. See H Natsuda et al., Ryumachi 34, 849 (1994). The use of the nitric oxide precursors such as L-arginine to produce warming secondary to vasodilation has been suggested. And a variety of indirect and non-definitive experiments have been conducted using oral administration. See M. Sonntag et al., Pflugers Arch 420,194 (1992); A. Agostoi et al., Int J Clin Lab Res 21, 202 (1991). Thus, while the literature contains suggestions that vasodilation by administration of oral L-arginine, the precursor of nitric oxide (endothelium-dependent relaxing factor), no reports exist of success in producing warming of tissue using this agent. In fact Dietz (see N Dietz et al., J Appl Physiol 76, 2047 (1994)) concludes from his data that “These data suggest that NO (nitric oxide) does not play a major role in cutaneous vasodilation during body heating in humans.” Further Singh (see S Singh et al., Eur J of Clin Invest 25, 182 (1995)) in a study of patients with Raynaud's phenomenon (severely cold hands and/or feet) concludes that L-arginine failed to cause vasodilation (and therefore warming) in patients with Raynaud's phenomenon.
    [0007] The literature contains no suggestions or examples of the use of L-arginine in any mode of administration for the growth of hair in male pattern baldness, healing of ulcers of the skin, impotence or for any other purpose. [0007]
    [0008] It has long been recognized that impaired blood flow to the penis is a major cause of erectile failure (impotence) in men. See A Moradian et al. [0008] Am J. Med 85, 748, (1988); T Hwang et al. J Formosan Med Assoc 89, 992 (1990). Further it has been recognized by using isolated tissue in vitro and in animal experiments that nitric oxide is an important mediator of relaxation of the vessels in penile cavernous tissue. See H Kirkeby et al. Acta Physiol Scand 149, 385 (1993). Topical nitroglycerine has been used in the treatment of impotence because of its ability to dilate vessels. The results were inconclusive and the treatment not well tolerated because of the cardiac response to nitroglycerine. See S Negelev J Urology 143, 586 (1990).
    [0009] It was discovered that topical application of the nitric oxide precursor, L-arginine, in its various forms including orally alone or in conjunction with a variety of topical preparations, either by themselves or with other agents to aid in penetration such as a high ionic strength environment, neutralization of its charge in a complex or by other means, or included in a liposome or other biological carrier, when administered to cold or cool tissue causes a substantial and prolonged warming effect in the tissue, grow hair on bald scalp, facilitate healing of superficial ulcers such as leg ulcers and overcome impotence in many subjects. [0009]
    [0010] In accordance with that invention, oral arginine by itself or in combination with a penetrating cream containing L-arginine at a concentration sufficient to produce an effect and sodium chloride or other salt at a concentration sufficient to create a hostile biophysical environment for the L-arginine in the cream is applied to the cold or cool tissue alone and/or in conjunction with oral arginine, exerts a warming effect which is prolonged, often lasting from 2-18 hours. In persons with very cold tissue (for example 22° C.) this warming effect can have a magnitude of 10° C. or more. [0010]
    [0011] Further, in accordance with this invention, oral L-arginine alone or in conjunction with a penetrating cream containing L-arginine in a concentration sufficient to produce the desired effect along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment when applied to bald areas of the scalp nightly either alone and/or in conjunction with oral arginine, produced growth of new hair within one month and substantial growth of hair within 3-4 months. [0011]
    [0012] Yet further, in accordance with this invention, oral arginine alone or in conjunction with a penetrating cream containing L-arginine in a concentration sufficient to produce the desired effect along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment when applied locally as the cream directly to the penis either alone and/or in conjunction with oral arginine, was effective in overcoming impotence. [0012]
    [0013] Consequently, with the discovery of the present invention, a means to warm cold and cool tissue, a problem shared by many, was developed for improving this uncomfortable and often painful problem in human health has been found. Further with the discovery of the present invention, a means to restore hair growth on a bald portion of scalp has been found. Still further, with the discovery of the present invention, a means effect healing of superficial ulcers such as leg ulcers has been found. Yet further, with the discovery of the present invention, a means to overcome impotence in many men has been found. [0013]
    [0014] These and other objects and features of the present invention will become apparent to those skilled in the art from reading the description of the invention, which follows. [0014] SUMMARY OF THE INVENTION
    [0015] Accordingly, several objects and advantages of the instant invention are to warm cold tissue in hands, feet or other tissue by increasing blood flow in the tissue means of enhancement of the body's natural mechanisms. It is further an object and advantage of the instant invention to prophylactically prevent tissue from becoming cold by use prior to entering into situations which induce cold hands and feet such as skiing or other winter outdoors activities. It is further an object and advantage of the instant invention to induce the growth of hair on bald portions of human scalp by means of enhancement of the body's natural mechanisms. It is yet another object of the instant invention to induce healing of superficial ulcers of the limbs by means of enhancement of the body's natural mechanisms. It is still further another object of the instant invention to provide a means for overcoming impotence in many men. [0015]
    [0016] In preferred embodiments, the delivery vehicles are capsules or tablets containing L-arginine used alone or in conjunction with a penetrating cream. In the cream the L-arginine is present as L-arginine hydrochloride in a concentration sufficient to produce the desired effect and the agent which creates the hostile biophysical environment is sodium chloride at a concentration sufficient to aid in tissue absorption. [0016] PREFERRED EMBODIMENTS
    [0017] The preferred embodiment consists tablets or capsules containing 200-500 mg of L-arginine to be used alone or in conjunction with a base cream with the properties of excellent absorption into the skin which also contains L-arginine hydrochloride (15% w/v) and sodium chloride (10% w/v). The components of the base cream may be those commonly found in hand creams. The purpose of L-arginine hydrochloride is to provide a precursor to the molecule, nitric oxide, NO. The purpose of the sodium chloride is to provide a high ionic strength environment for the highly charged molecule, L-arginine. The base cream containing L-arginine and sodium chloride is the agent which is applied to the hands and/or feet to produce to produce a warming effect in the tissue, to produce hair growth or to effect healing of ulcers such as leg ulcers, or directly to the penis in order to aid in overcoming impotence. [0017]
    [0018] The treatment consisting of oral administration of capsules or tablets containing L-arginine used alone or in conjunction with the cream acts effectively to warm cold tissue such as hands, fingers, feet, toes or other tissue when applied to the tissue and rubbed into the tissue to assure maximal absorption. The warming effect, caused by increased blood flow in the tissue is not instant but begins within 5 to 20 minutes. The effect is long lasting. Often the tissue remains warm for more than 2 to 18 hours. The treatment consisting of oral administration of capsules or tablets containing L-arginine used alone or in conjunction with the cream acts effectively to induce hair growth on bald human scalp when applied nightly to the bald area each night for several months. Hair growth is naturally a slow process. However, substantial hair growth is achieved over large areas of scalp with results becoming evident in a few weeks and substantial within several months. The cream further acts to promote healing of superficial ulcers such as those sometimes found on the legs of persons with severe diabetes. Application twice daily for a period of two weeks causes substantial healing and in many cases complete healing is achieved within this time period or slightly longer (3-4 weeks). Further the treatment consisting of oral administration of L-arginine used alone or in conjunction with the cream when carried out daily for a period of 7-10 days and then maintained with daily administration causes substantial relief from impotence in many men. [0018] OTHER EMBODIMENTS
    [0019] Other active agents [0019]
    [0020] While L-arginine hydrochloride is the preferred active agent because it is the agent in nature itself, it is non-toxic, is highly soluble and it is inexpensive, other agents could be used which are also precursors or donors of nitric oxide. These include the salt, arginine glutamate, the salt, arginine butyrate, and esters of arginine such as arginine ethyl ester or arginine butyl ester as well as other donors of nitric oxide. [0020]
    [0021] In the case an alternative active agent were used it would be simply substituted for L-arginine in a delivery preparation and the preparation used as in the case of the L-arginine preparation. [0021]
    [0022] Other means of effecting absorption [0022]
    [0023] A variety of means for effecting absorption of the active agent from the topical cream might be envisioned. One principle behind the absorption of a highly charged molecule such as L-arginine into tissue is to either create a biophysically hostile environment in the delivery vehicle such that L-arginine would prefer to be in tissue, or to package L-arginine in such a way that it is carried into tissue or neutralize its charge by derivitization or forming a neutral salt. Examples of biophysically hostile environments, include but are not limited to, high ionic strength, high or low pH, and highly hydrophobic environments. Examples of packaging which would be carried into tissue includes liposomes or emulsions of collagen, collagen peptides or other components of skin or basement membrane. Examples of neutralization of charge include the salt, arginine glutamate which is electronically neutral. [0023]
    [0024] In each case of creating a hostile biophysical environment for the active agent, the agent was added to an appropriate preparation. In the case of creating a high ionic strength ions such as but not limited to sodium chloride, potassium chloride, choline chloride, lithium chloride, alone or in combination were added in high concentration. Other highly charged molecules such as polylysine, polyglutamine, polyaspartate or copolymers of such charged amino acids may be used to create the hostile biophysical environment. Alternatively a hostile biophysical environment may be created by placing the highly charged L-arginine in an hydrophobic, oily environment such as in an oil-based cream containing little or no water. [0024] EXAMPLE 1
    [0025] In this example a person with very cold fingers was provided with the above warming cream consisting of a delivery vehicle of penetrating cream, L-arginine hydrochloride (15% w/v), and sodium chloride (10% w/v). The surface temperature of the subject fingers of the left hand varied from 21 to 24° C. The warming cream was applied through rubbing into the skin. Surface temperatures of each finger were measured each 15 minutes for the initial hour. At 15 minutes following administration of the warming cream the effect had begun to occur with surface temperatures or various fingers rising to 26 to 29° C. The maximal effect was reached by 45 minutes with surface temperatures of various fingers becoming 31 to 34° C. The effect was sustained at least 4 hours. [0025] EXAMPLE 2
    [0026] In this example a 53 year old man with baldness consisting of a severely receding hairline as well as large “bald spot” on the top rear of his head was provided with a penetrating cream containing L-arginine hydrochloride (15% w/v) and sodium chloride (10% w/v). The cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months the receding hairline (previously 4 cm of bald skin) had returned to normal and the “bald spot” previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with even this area showing some new hair growth. [0026] EXAMPLE 3
    [0027] In a 54 year old man with a history of impotence administration of 1.5 g L-arginine daily in the form of oral capsules combined with twice daily administration of a penetrating cream containing L-arginine hydrochloride (15% w/v) and sodium chloride (10% w/v) directly to the penis for 7 days brought initial relief from the symptoms of impotence and allowed the subject to resume normal sexual activity. This relief of symptoms was maintained by continuation of the treatment daily. [0027]
    [0028] Accordingly, it can be seen that in the present invention I have provided a method and agents, which when applied to cold, and often painful tissue, an increase in skin temperature results through utilization of one of the body's own mechanisms for producing warmth. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide, is produced. Nitric oxide causes increases in local blood flow which results in warming. Further, it can be seen that in the present invention I have provided a method and agents which when applied to bald scalp causes hair growth through utilization of one of the body's own mechanisms. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide is produced. Nitric oxide causes increases in local blood flow which enables the growth of hair. Still further it can be seen that in the present invention I have provided a method and agents which when applied to leg ulcers cause healing through use of the body's own mechanisms. Yet still further, it can be seen that in the present invention I have provided a method and agents which when applied to a person with impotence causes overcoming of impotence by use of the body's own mechanisms. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide is produced. Nitric oxide causes increases in local blood flow allowing the body's own healing cells and substances to reach the ulcer site. [0028]
    [0029] Although the description above contains many specificities, these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the presently preferred embodiments of this invention. Various other embodiments and ramifications are possible within this scope. [0029]
    [0030] Thus the scope of the invention should be determined by the appended claims and their legal equivalents, rather than by the examples given. [0030]
    权利要求:
    Claims (60)
    [1" id="US-20010002405-A1-CLM-00001] 1. A method for delivering a nitric oxide precursor to an area of the body for the purpose of increasing local blood flow.
    [2" id="US-20010002405-A1-CLM-00002] 2. The method of
    claim 1 where the delivery vehicle is orally administered forms of L-arginine such as capsules, tablets, liquid or other oral form in dosage sufficient to produce the desired effect.
    [3" id="US-20010002405-A1-CLM-00003] 3. The method of
    claim 1 where the delivery vehicles are orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [4" id="US-20010002405-A1-CLM-00004] 4. The method of
    claim 1 where the delivery vehicle are orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [5" id="US-20010002405-A1-CLM-00005] 5. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream of hydrophobic nature containing little or no water, but oils, waxes and other hydrophobic substances, containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [6" id="US-20010002405-A1-CLM-00006] 6. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes or liposome like structures which contain within them L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [7" id="US-20010002405-A1-CLM-00007] 7. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide extra force to cause absorption of the L-arginine species.
    [8" id="US-20010002405-A1-CLM-00008] 8. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [9" id="US-20010002405-A1-CLM-00009] 9. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide extra force to cause tissue absorption of the L-arginine species.
    [10" id="US-20010002405-A1-CLM-00010] 10. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine hydrochloride (0.25% to 25%) and sodium chloride (0.25% to 25%).
    [11" id="US-20010002405-A1-CLM-00011] 11. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine glutamate (0.25% to 25%) and sodium chloride (0.25%-25%).
    [12" id="US-20010002405-A1-CLM-00012] 12. The method of
    claim 1 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine (0.25% to 25%) and choline chloride (0.25% to 25%).
    [13" id="US-20010002405-A1-CLM-00013] 13. A method for warming cool or cold tissue by providing, through means of a delivery vehicle, to the cold or cool tissue an effective dose of a precursor to the endothelial relaxing factor, nitric oxide.
    [14" id="US-20010002405-A1-CLM-00014] 14. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine contained in capsules, tablets, liquid or other oral form in dosage sufficient to cause the desired effect.
    [15" id="US-20010002405-A1-CLM-00015] 15. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, and ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [16" id="US-20010002405-A1-CLM-00016] 16. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [17" id="US-20010002405-A1-CLM-00017] 17. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream of hydrophobic nature containing oils, waxes and other hydrophobic materials and little water sufficient to aid in the absorption of the nitric oxide precursor L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [18" id="US-20010002405-A1-CLM-00018] 18. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [19" id="US-20010002405-A1-CLM-00019] 19. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide extra force to cause absorption of the L-arginine species.
    [20" id="US-20010002405-A1-CLM-00020] 20. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine administered in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [21" id="US-20010002405-A1-CLM-00021] 21. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine administered in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [22" id="US-20010002405-A1-CLM-00022] 22. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) administered in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine hydrochloride (0.25% to 25%) and sodium chloride (0.25% to 25%).
    [23" id="US-20010002405-A1-CLM-00023] 23. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) administered in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine glutamate (0.25% to 25%) and sodium chloride (0.25%-25%).
    [24" id="US-20010002405-A1-CLM-00024] 24. The method of
    claim 13 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) administered in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine (0.25% to 25%) and choline chloride (0.25% to 25%).
    [25" id="US-20010002405-A1-CLM-00025] 25. A method for promoting hair growth on bald scalp, through means of a delivery vehicle, to the bald scalp an effective dose of a precursor to the endothelial relaxing factor, nitric oxide.
    [26" id="US-20010002405-A1-CLM-00026] 26. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine contained in capsules, tablets, liquid or other oral form at a dosage sufficient to obtain the desired effect.
    [27" id="US-20010002405-A1-CLM-00027] 27. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine administered in conjunction with a penetrating cream, a liquid, a lotion, and ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [28" id="US-20010002405-A1-CLM-00028] 28. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine use in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [29" id="US-20010002405-A1-CLM-00029] 29. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream of hydrophobic nature containing oils, waxes and other hydrophobic materials and little water sufficient to aid in the absorption of the nitric oxide precursor L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [30" id="US-20010002405-A1-CLM-00030] 30. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [31" id="US-20010002405-A1-CLM-00031] 31. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide extra force to cause absorption of the L-arginine species.
    [32" id="US-20010002405-A1-CLM-00032] 32. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [33" id="US-20010002405-A1-CLM-00033] 33. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [34" id="US-20010002405-A1-CLM-00034] 34. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine hydrochloride (0.25% to 25%) and sodium chloride (0.25% to 25%).
    [35" id="US-20010002405-A1-CLM-00035] 35. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine glutamate (0.25% to 25%) and sodium chloride (0.25%-25%).
    [36" id="US-20010002405-A1-CLM-00036] 36. The method of
    claim 25 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine (0.25% to 25%) and choline chloride (0.25% to 25%).
    [37" id="US-20010002405-A1-CLM-00037] 37. A method for promoting healing of superficial ulcers such as leg ulcers secondary to diabetes or other causes, through means of a delivery vehicle, to the ulcer and the area surrounding it an effective dose of a precursor to the endothelial relaxing factor, nitric oxide.
    [38" id="US-20010002405-A1-CLM-00038] 38. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine in capsules, tablets, liquid or other oral forms in a dosage sufficient to produce the desired effect.
    [39" id="US-20010002405-A1-CLM-00039] 39. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, and ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [40" id="US-20010002405-A1-CLM-00040] 40. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [41" id="US-20010002405-A1-CLM-00041] 41. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine administered in conjunction with a penetrating cream of hydrophobic nature containing oils, waxes and other hydrophobic materials and little water sufficient to aid in the absorption of the nitric oxide precursor L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [42" id="US-20010002405-A1-CLM-00042] 42. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [43" id="US-20010002405-A1-CLM-00043] 43. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide extra force to cause absorption of the L-arginine species.
    [44" id="US-20010002405-A1-CLM-00044] 44. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [45" id="US-20010002405-A1-CLM-00045] 45. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [46" id="US-20010002405-A1-CLM-00046] 46. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine hydrochloride (0.25% to 25%) and sodium chloride (0.25% to 25%).
    [47" id="US-20010002405-A1-CLM-00047] 47. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine glutamate (0.25% to 25%) and sodium chloride (0.25%-25%).
    [48" id="US-20010002405-A1-CLM-00048] 48. The method of
    claim 37 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine (0.25% to 25%) and choline chloride (0.25% to 25%).
    [49" id="US-20010002405-A1-CLM-00049] 49. A method for overcoming impotence by delivering to the penis an effective dose of a precursor to the endothelial relaxing factor, nitric oxide.
    [50" id="US-20010002405-A1-CLM-00050] 50. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine in capsules, tablets, liquid or other oral forms in a dosage sufficient to produce the desired effect.
    [51" id="US-20010002405-A1-CLM-00051] 51. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, and ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [52" id="US-20010002405-A1-CLM-00052] 52. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [53" id="US-20010002405-A1-CLM-00053] 53. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine administered in conjunction with a penetrating cream of hydrophobic nature containing oils, waxes and other hydrophobic materials and little water sufficient to aid in the absorption of the nitric oxide precursor L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [54" id="US-20010002405-A1-CLM-00054] 54. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [55" id="US-20010002405-A1-CLM-00055] 55. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine used in conjunction with a penetrating cream, a liquid, a lotion, an ointment or other topical preparation containing liposomes in which are encapsulated L-arginine, salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide extra force to cause absorption of the L-arginine species.
    [56" id="US-20010002405-A1-CLM-00056] 56. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose.
    [57" id="US-20010002405-A1-CLM-00057] 57. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine used in conjunction with a trans-dermal patch or its equivalent where the patch contains L-arginine, a salt or salts of L-arginine, a complex of L-arginine or a derivative of L-arginine in an effective dose in addition to other ionic salts such as to create an ionic strength environment high enough to provide an extra force to cause tissue absorption of the L-arginine species.
    [58" id="US-20010002405-A1-CLM-00058] 58. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine hydrochloride (0.25% to 25%) and sodium chloride (0.25% to 25%).
    [59" id="US-20010002405-A1-CLM-00059] 59. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine glutamate (0.25% to 25%) and sodium chloride (0.25%-25%).
    [60" id="US-20010002405-A1-CLM-00060] 60. The method of
    claim 49 where the delivery vehicle is orally administered L-arginine (0.5-30 g/day) used in conjunction with a cream containing water, aloe vera, mineral oil, glycerol stearate, squalene, wheat germ oil, cetyl alcohol, propylene glycol stearate, polysorbate 60, propylene glycol, vitamin E, hyaluronic acid/collagen, vitamin A, vitamin D, sorbitan stearate, triethanolamine, imidazolidinyl urea, methylparaben, propylparaben, bha, L-arginine (0.25% to 25%) and choline chloride (0.25% to 25%).
    类似技术:
    公开号 | 公开日 | 专利标题
    US6458841B2|2002-10-01|Topical and oral delivery of arginine to cause beneficial effects
    US5895658A|1999-04-20|Topical delivery of L-arginine to cause tissue warming
    CA2303394C|2011-12-20|A delivery of arginine to cause beneficial effects
    US8603519B2|2013-12-10|Topical delivery of L-arginine to cause beneficial effects
    US7629384B2|2009-12-08|Topical delivery of L-arginine to cause beneficial effects
    US5922332A|1999-07-13|Topical delivery of arginine to overcome pain
    JP2002515401A5|2008-07-10|
    EP1732577B1|2013-04-10|Topical delivery of l-arginine to improve body and skin appearance
    US5425954A|1995-06-20|Topical amino acid - vitamin complex compositions for pharmaceutical and cosmetic use
    JP3157823B2|2001-04-16|Water-containing paste-type pharmaceutical composition
    CA1166575A|1984-05-01|Therapeutic dimethyl sulfoxide composition andmethods of use
    US20090123528A1|2009-05-14|Transdermal delivery of beneficial substances effected by a hostile biophysical environment
    JPH10511110A|1998-10-27|Use of extracts from non-photosynthetic filamentous bacteria and compositions containing them
    US5032400A|1991-07-16|Shark liver oil and garlic oil topical analgesic
    JPH08500092A|1996-01-09|Dermatological composition
    ALBRIGHT et al.1966|Rapid treatment of tinea versicolor with selenium sulfide
    EP2691103B1|2016-07-20|Method for treating disorders of the skin
    WO1994005279A1|1994-03-17|Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid
    CA2551690A1|2007-02-08|Compositions for use with skin
    LeVan et al.1954|The use of silicones in dermatology
    JP3909008B2|2007-04-25|Keratinase inhibitor and skin external preparation containing the same
    JPH07300419A|1995-11-14|Composition of lanolin/lanolin acid ester for treating skin
    MXPA97010478A|1998-11-12|Use of an abstract of a non-photosintetic filamentosa bacteria and composition that the conti
    同族专利:
    公开号 | 公开日
    US20030018076A1|2003-01-23|
    US6458841B2|2002-10-01|
    US6207713B1|2001-03-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20040047919A1|2002-06-13|2004-03-11|Board Of Regents, The University Of Texas System|Methods and compositions involving aldose reductase inhibitors|
    US20090270490A1|2008-04-24|2009-10-29|The Board Of Regents Of The University Of Texas System|Methods involving aldose reductase inhibition|
    US20100144748A1|2007-03-23|2010-06-10|Srivastava Satish K|Methods involving aldose reductase inhibitors|
    US20110092566A1|2004-11-19|2011-04-21|Srivastava Satish K|Treatment of cancer with aldose reductase inhibitors|US4681897A|1984-01-16|1987-07-21|The Procter & Gamble Company|Pharmaceutical products providing enhanced analgesia|
    US4732892A|1985-07-12|1988-03-22|American Home Products Corporation|L-α-amino acids as transdermal penetration enhancers|
    US5925372A|1987-12-16|1999-07-20|Novartis Corporation|Mixed solvent mutually enhanced transdermal therapeutic system|
    US4871718A|1987-12-29|1989-10-03|Raymond A. Roncari|Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair|
    US5476852A|1989-05-03|1995-12-19|Janssen Pharmaceutica N.V.|Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin|
    US5028435A|1989-05-22|1991-07-02|Advanced Polymer Systems, Inc.|System and method for transdermal drug delivery|
    US5576351A|1989-12-29|1996-11-19|Mcgaw, Inc.|Use of arginine as an immunostimulator|
    DE4100975A1|1991-01-15|1992-07-16|Weuffen Wolfgang|Cosmetic or pharmaceutical preparations for improving hair quality and promoting hair growth|
    CA2105313A1|1991-03-01|1992-09-02|Rafael Abad|Therapeutic and cosmetic compositions for treatment of skin|
    US5405919A|1992-08-24|1995-04-11|The United States Of America As Represented By The Secretary Of Health And Human Services|Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders|
    US5632981A|1992-08-24|1997-05-27|The United States Of America As Represented By The Department Of Health And Human Services|Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same|
    US5691423A|1992-08-24|1997-11-25|The United States Of America As Represented By The Department Of Health And Human Services|Polysaccharide-bound nitric oxide-nucleophile adducts|
    US5428070A|1993-06-11|1995-06-27|The Board Of Trustees Of The Leland Stanford Junior University|Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity|
    US5891459A|1993-06-11|1999-04-06|The Board Of Trustees Of The Leland Stanford Junior University|Enhancement of vascular function by modulation of endogenous nitric oxide production or activity|
    US5714472A|1993-12-23|1998-02-03|Nestec Ltd.|Enternal formulation designed for optimized nutrient absorption and wound healing|
    US5543430A|1994-10-05|1996-08-06|Kaesemeyer; W. H.|Method and formulation of stimulating nitric oxide synthesis|
    US5505958A|1994-10-31|1996-04-09|Algos Pharmaceutical Corporation|Transdermal drug delivery device and method for its manufacture|
    US5648101A|1994-11-14|1997-07-15|Tawashi; Rashad|Drug delivery of nitric oxide|
    US5853768A|1995-03-01|1998-12-29|Altadonna; James|Topical preparation and method for pain relief|
    US5595753A|1995-04-14|1997-01-21|President And Fellows Of Harvard College|Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract|
    US5698738A|1995-05-15|1997-12-16|Board Of Regents, The University Of Texas System|N-nitroso-N-substituted hydroxylamines as nitric oxide donors|
    US5789442A|1996-01-18|1998-08-04|Schering Aktiengesellschaft|Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents|
    WO1999001427A2|1997-07-03|1999-01-14|The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health|Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same|
    US6207713B1|1997-09-17|2001-03-27|Eric T. Fossel|Topical and oral delivery of arginine to cause beneficial effects|
    US5922332A|1997-09-17|1999-07-13|Fossel; Eric T.|Topical delivery of arginine to overcome pain|
    US5895658A|1997-09-17|1999-04-20|Fossel; Eric T.|Topical delivery of L-arginine to cause tissue warming|
    US6096759A|1997-09-19|2000-08-01|Georgetown University|Method for treating essential hypertension|
    GB9801398D0|1998-01-22|1998-03-18|Anggard Erik E|Chemical compounds|
    US6103275A|1998-06-10|2000-08-15|Nitric Oxide Solutions|Systems and methods for topical treatment with nitric oxide|
    US6117872A|1998-06-23|2000-09-12|The Board Of Trustees Of The Leland Stanford Junior University|Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity|
    US6261594B1|1998-11-25|2001-07-17|The University Of Akron|Chitosan-based nitric oxide donor compositions|
    US6538033B2|2000-08-29|2003-03-25|Huntington Medical Research Institutes|Nitric oxide donor compounds|US6331543B1|1996-11-01|2001-12-18|Nitromed, Inc.|Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use|
    US6207713B1|1997-09-17|2001-03-27|Eric T. Fossel|Topical and oral delivery of arginine to cause beneficial effects|
    US7914814B2|1997-09-17|2011-03-29|Strategic Science & Technologies, Llc|Topical delivery of arginine of cause beneficial effects|
    US7629384B2|1997-09-17|2009-12-08|Strategic Science & Technologies, Llc|Topical delivery of L-arginine to cause beneficial effects|
    GB9905425D0|1999-03-09|1999-05-05|Queen Mary & Westfield College|Pharmaceutical composition|
    AU4013900A|1999-03-19|2000-10-09|Enos Pharmaceuticals, Inc.|Increasing cerebral bioavailability of drugs|
    US6476037B1|2000-03-23|2002-11-05|The Regents Of The University Of California|L-arginine and phosphodiesteraseinhibitor synergism|
    US7128930B1|2000-09-01|2006-10-31|Meir S. Sacks|Compositions and methods for treating sexual dysfunction|
    US6444237B1|2001-09-13|2002-09-03|Pamela A. Heleen|Herbal composition for enhancing sexual response|
    US20040018237A1|2002-05-31|2004-01-29|Perricone Nicholas V.|Topical drug delivery using phosphatidylcholine|
    AU2004279298B2|2003-09-29|2009-01-29|Palmetto Pharmaceuticals, Llc|Sustained release L-arginine formulations and methods of manufacture and use|
    CA2503284A1|2002-10-24|2004-05-06|Enos Pharmaceuticals, Inc.|Sustained release l-arginine formulations and methods of manufacture and use|
    US20080145424A1|2002-10-24|2008-06-19|Enos Phramaceuticals, Inc.|Sustained release L-arginine formulations and methods of manufacture and use|
    WO2004071437A2|2003-02-07|2004-08-26|Barmensen, Inc.|Compositions for enhancing sexual responsiveness|
    US20040254238A1|2003-04-07|2004-12-16|Osteoscreen|Bone growth stimulation with NO/statin and other NO modulating combinations|
    US20080045909A1|2004-02-23|2008-02-21|Strategic Science & Technologies, Llc.|Topical Delivery of a Nitric Oxide Donor to Improve and Skin Appearance|
    US20050196433A1|2004-03-04|2005-09-08|Brierre Barbara T.|Pharmaceutical composition and method for the transdermal delivery of magnesium|
    US20050282751A1|2004-03-19|2005-12-22|Ajinomoto Co., Inc.|Therapeutic agent for renal anemia|
    AU2012201048B2|2004-04-19|2013-06-06|Strategic Science & Technologies, Llc|Transdermal delivery of beneficial substances effected by a hostile biophysical environment|
    US20090105336A1|2004-04-19|2009-04-23|Strategic Science & Technologies, Llc|Beneficial Effects of Increasing Local Blood Flow|
    US20110028548A1|2004-04-19|2011-02-03|Strategic Science & Technologies, Llc|Beneficial effects of increasing local blood flow|
    CA2563670C|2004-04-19|2014-09-16|Strategic Science & Technologies, Llc|Transdermal delivery of beneficial substances effected by a hostile biophysical environment|
    CA2835840C|2004-04-19|2016-06-14|Strategic Science & Technologies, Llc|Beneficial effects of increasing local blood flow|
    US9226909B2|2004-04-19|2016-01-05|Strategic Science & Technologies, Llc|Beneficial effects of increasing local blood flow|
    US8673341B2|2004-04-30|2014-03-18|Allergan, Inc.|Intraocular pressure reduction with intracameral bimatoprost implants|
    HU0401422A2|2004-07-15|2006-04-28|G Laszlo Meszaros|Use of l-arginine as vasoaktive ingredient absorbing through skin for external application|
    US20050148669A1|2004-10-21|2005-07-07|Daniel Amato|Amino acid esters as nutrient supplements and methods of use|
    US8445536B2|2005-03-31|2013-05-21|Ajinomoto Co., Inc.|Arginine-containing compositions and methods for increasing blood flow using same|
    FR2903309B1|2006-07-07|2008-10-10|Labo Dermatologiques D Uriage|COSMETIC AND DERMATOLOGICAL COMPOSITIONS FOR FIGHT AGAINST HAIR DROP|
    WO2008038771A1|2006-09-29|2008-04-03|Ajinomoto Co., Inc.|Glutamine-containing composition for increasing blood flow|
    US8343486B2|2008-01-22|2013-01-01|Biochemics, Inc.|Methods and compositions for topical treatment of medical conditions including wounds and inflammation|
    CA2727710C|2008-06-11|2016-11-01|Biochemics, Inc.|Control of blood vessel physiology to treat skin disorders|
    CA2726726A1|2008-09-10|2010-03-18|Thrubit B.V.|Ibuprofen for topical administration|
    BRPI0914192A2|2008-09-22|2015-11-03|Biochemics Inc|transdermal drug delivery using an osmolyte and vasoactive agent|
    EP2352543B1|2008-12-04|2019-04-03|BioChemics, Inc.|Methods and compositions for tattoo removal|
    US20100286587A1|2009-05-07|2010-11-11|Yossi Gross|Sublingual electrical drug delivery|
    EP3045171A1|2009-06-24|2016-07-20|Strategic Science & Technologies, LLC|Topical composition|
    WO2010151241A1|2009-06-24|2010-12-29|Strategic Science & Technologies, Llc|Topical composition containing naproxen|
    US9463158B2|2009-06-24|2016-10-11|Strategic Science & Technologies, Llc|Treatment of erectile dysfunction and other indications|
    JP2014501283A|2010-12-29|2014-01-20|ストラテジックサイエンスアンドテクノロジーズ，エルエルシー|Systems and methods for the treatment of allergies and other indications|
    WO2012125214A1|2011-03-17|2012-09-20|Transdermal Biotechnology, Inc.|Topical nitric oxide systems and methods of use thereof|
    US8871260B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Methods and compositions for muscular and neuromuscular diseases|
    US8871258B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Treatment and prevention of learning and memory disorders|
    US8871254B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system|
    US8871261B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Cancer treatments and compositions for use thereof|
    US8871256B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Methods and systems for treatment of inflammatory diseases with nitric oxide|
    US8871255B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Treatment of skin and soft tissue infection with nitric oxide|
    US8871257B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery|
    US8871259B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Techniques and systems for treatment of neuropathic pain and other indications|
    US8871262B2|2012-09-19|2014-10-28|Transdermal Biotechnology, Inc.|Compositions and methods for treatment of osteoporosis and other indications|
    US9849160B2|2013-03-13|2017-12-26|Transdermal Biotechnology, Inc.|Methods and systems for treating or preventing cancer|
    US9295647B2|2013-03-13|2016-03-29|Transdermal Biotechnology, Inc.|Systems and methods for delivery of peptides|
    US9393264B2|2013-03-13|2016-07-19|Transdermal Biotechnology, Inc.|Immune modulation using peptides and other compositions|
    US20140271731A1|2013-03-13|2014-09-18|Transdermal Biotechnology, Inc.|Cardiovascular disease treatment and prevention|
    US9387159B2|2013-03-13|2016-07-12|Transdermal Biotechnology, Inc.|Treatment of skin, including aging skin, to improve appearance|
    US9314433B2|2013-03-13|2016-04-19|Transdermal Biotechnology, Inc.|Methods and systems for treating or preventing cancer|
    US9320758B2|2013-03-13|2016-04-26|Transdermal Biotechnology, Inc.|Brain and neural treatments comprising peptides and other compositions|
    US20140271937A1|2013-03-13|2014-09-18|Transdermal Biotechnology, Inc.|Brain and neural treatments comprising peptides and other compositions|
    US9393265B2|2013-03-13|2016-07-19|Transdermal Biotechnology, Inc.|Wound healing using topical systems and methods|
    US9314422B2|2013-03-13|2016-04-19|Transdermal Biotechnology, Inc.|Peptide systems and methods for metabolic conditions|
    US20140271938A1|2013-03-13|2014-09-18|Transdermal Biotechnology, Inc.|Systems and methods for delivery of peptides|
    US9314423B2|2013-03-13|2016-04-19|Transdermal Biotechnology, Inc.|Hair treatment systems and methods using peptides and other compositions|
    US9295637B2|2013-03-13|2016-03-29|Transdermal Biotechnology, Inc.|Compositions and methods for affecting mood states|
    US9724419B2|2013-03-13|2017-08-08|Transdermal Biotechnology, Inc.|Peptide systems and methods for metabolic conditions|
    US9295636B2|2013-03-13|2016-03-29|Transdermal Biotechnology, Inc.|Wound healing using topical systems and methods|
    US9750787B2|2013-03-13|2017-09-05|Transdermal Biotechnology, Inc.|Memory or learning improvement using peptide and other compositions|
    US9687520B2|2013-03-13|2017-06-27|Transdermal Biotechnology, Inc.|Memory or learning improvement using peptide and other compositions|
    US9241899B2|2013-03-13|2016-01-26|Transdermal Biotechnology, Inc.|Topical systems and methods for treating sexual dysfunction|
    US9339457B2|2013-03-13|2016-05-17|Transdermal Biotechnology, Inc.|Cardiovascular disease treatment and prevention|
    US9314417B2|2013-03-13|2016-04-19|Transdermal Biotechnology, Inc.|Treatment of skin, including aging skin, to improve appearance|
    US9320706B2|2013-03-13|2016-04-26|Transdermal Biotechnology, Inc.|Immune modulation using peptides and other compositions|
    EP2968130A1|2013-03-15|2016-01-20|Strategic Science & Technologies, LLC|Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors|
    JP2016513686A|2013-03-15|2016-05-16|ストラテジック サイエンス アンド テクノロジーズ， エルエルシー|Fluticasone transdermal formulation|
    GR1008308B|2013-05-31|2014-10-02|UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE",|Local pharmaceutical and medi-tech compositions containing combinations of sucralfat, hyaluronic acid, arginine and one natural moistening factor|
    US10226418B2|2014-05-12|2019-03-12|Susie Q, Ltd.|Arginine-containing topical composition|
    WO2016112201A1|2015-01-07|2016-07-14|Strategic Science & Technologies, Llc|Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications|
    US10653549B2|2017-07-18|2020-05-19|Carl W. Lange, IV|Topical medication method for erectile dysfunction|
    法律状态:
    2002-09-12| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2005-09-23| AS| Assignment|Owner name: STRATEGIC SCIENCE & TECHNOLOGIES, LLC, MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOSSEL, ERIC THOR;REEL/FRAME:016835/0806 Effective date: 20050712 |
    2006-04-03| FPAY| Fee payment|Year of fee payment: 4 |
    2010-05-10| REMI| Maintenance fee reminder mailed|
    2010-09-27| FPAY| Fee payment|Year of fee payment: 8 |
    2010-09-27| SULP| Surcharge for late payment|Year of fee payment: 7 |
    2014-04-01| FPAY| Fee payment|Year of fee payment: 12 |
    优先权:
    申请号 | 申请日 | 专利标题
    US08/936,189|US6207713B1|1997-09-17|1997-09-17|Topical and oral delivery of arginine to cause beneficial effects|
    US09/734,096|US6458841B2|1997-09-17|2000-12-11|Topical and oral delivery of arginine to cause beneficial effects|US09/734,096| US6458841B2|1997-09-17|2000-12-11|Topical and oral delivery of arginine to cause beneficial effects|
    US10/213,286| US20030018076A1|1997-09-17|2002-08-05|Topical and oral arginine to cause beneficial effects|
    [返回顶部]